Qiagen has identified Parse Biosciences’ technology as complementary to its sample technology and bioinformatic businesses.

Ultra-low-pass whole genome sequencing (ULP-WGS) of circulating tumor DNA appears to provide important prognostic information regarding patients with large B-cell lymphoma (LBCL), according to ...

FDA recently issued the draft guidance, Quality Management System Information for Certain Premarket Submission Reviews. The guidance is designed ...

Hospitals, diagnostic laboratories, and research institutions are rapidly adopting PCR and sequencing technologies to enhance ...

The global sales of microbial identification are estimated to be worth USD 4.69 billion in 2025 and anticipated to reach a ...